For weight management, NICE has approved: Semaglutide 2.4 mg (TA875) for adults with a BMI of 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity, and for some people with BMI 30-34.9 kg/m meeting specific criteria
But GLP-1 drugs are meant to be taken long-term, not just for an event, both Levy and McGowan emphasize, warning that stopping or interrupting therapy can lead weight regain and increased side effects
So its not the first metric to look The metric of success really is our muscle mass, which isnt what the scale will tell us, a regular scale, right
in 2014, a weekly SC formulation was developed, and the indication for weight loss was approved by the FDA
Open 8 , e2521887 (2025)
This marks a sharp rise from 4.1% of households in 2025 and 2.3% in 2024